Previous 10 | Next 10 |
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) will release its third quarter 2019 financial results on Wednesday, November 6, 2019, prior to the open of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community at 8:30 a.m., Eastern Time ...
After losing more than 77% of its total enterprise value in less than four years, Akorn, Inc. ( AKRX ) is a name to be followed carefully. The most significant risk is the company’s financial debt, which does not justify the current low valuation. Besides, Akorn recently announced tha...
- Company granted 180 days of exclusivity under FDA Competitive Generic Therapy approval pathway - Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its generic version of Amicar ® (am...
The Trump administration has allocated $1.8B to help states and local governments tackle opioid addiction in their respective areas. The funds will be distributed through Substance Abuse and Mental Health Services and the CDC for treatment and data gathering. More news on: Teva Pharmaceu...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that members of management will participate in a fireside chat at the Morgan Stanley 17 th Annual Global Healthcare Conference in New York on Tuesday, September 10, 2019 at 2:55 p.m. Eastern Time. To access a live webcast of the p...
Certain opioid painkiller makers are under pressure in apparent response to Allergan's agreement to pay $5M to settle all claims connected to the federal suit in Ohio related to the opioid epidemic, a situation that the company had relatively little to do with. Investors appear to perceive...
Quick Take TFF Pharmaceuticals ( TFFP ) has filed to raise gross proceeds of $22 million from a U.S. IPO, according to an S-1 registration statement . The firm is focused on developing and commercializing treatments for lung-related conditions. TFFP is proposing a fairly low valuation a...
Image source: The Motley Fool. Amneal Pharmaceuticals, Inc. (NYSE: AMRX) Q2 2019 Earnings Call August 5, 2019, 8:30 a.m. ET Operator Continue reading
U.S. Senator Bernie Sanders (I-VT) and Representative Elijah Cummings (D-MD - 7th district) have launched an investigation targeting Teva Pharmaceutical Industries ( TEVA -8% ), Mylan N.V. ( MYL -7.8% ) and Heritage Pharmaceuticals for allegedly obstructing a Congressional inquiry into...
InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...
News, Short Squeeze, Breakout and More Instantly...
Amneal Pharmaceuticals Inc. Class A Company Name:
AMRX Stock Symbol:
NASDAQ Market:
Amneal Pharmaceuticals Inc. Class A Website:
First presentation of preservative-free potassium phosphates in a single-dose IV infusion bag Third 505(b)(2) injectable added this year – will launch in third quarter Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) to...
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...
FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC and MEC) Second injectable RTU product launched by Amneal in 2024 Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”...